Skip to main content
. 2024 Oct 18;16(6):601–612. doi: 10.4168/aair.2024.16.6.601

Table 1. Characteristics of study participants.

Variable Low IgE ACO (n = 44) High IgE ACO (n = 104) P value Atopy (−) ACO (n = 95) Atopy (+) ACO (n = 79) P value Low blood eosinophil ACO (n = 103) High blood eosinophil ACO (n = 210) P value Low sputum eosinophil ACO (n = 25) High sputum eosinophil ACO (n = 37) P value
Age (yr) 63.0 ± 11.0 61.6 ± 9.7 0.463 63.4 ± 9.4 60.4 ± 9.9 0.046 64.6 ± 9.9 62.2 ± 10.3 0.047 61.0 ± 9.6 65.0 ± 11.9 0.168
Male 37 (84.1%) 96 (92.3%) 0.224 84 (88.4%) 74 (93.7%) 0.353 89 (86.4%) 197 (93.8%) 0.048 24 (96.0%) 34 (91.9%) 0.905
BMI (kg/m2) 24.7 ± 3.0 24.1 ± 2.7 0.285 24.4 ± 3.0 24.5 ± 2.5 0.719 24.0 ± 3.1 24.6 ± 3.9 0.143 24.2 ± 2.7 25.6 ± 7.4 0.317
Smoking (pack-year) 35.5 ± 24.49 34.6 ± 21.0 0.836 37.0 ± 21.7 31.4 ± 17.8 0.067 33.7 ± 20.2 36.0 ± 22.8 0.388 36.3 ± 15.5 35.3 ± 18.9 0.836
Allergic rhinitis 3 (6.8%) 26 (25.0%) 0.02 11 (11.6%) 25 (31.7%) 0.002 15 (14.6%) 53 (25.2%) 0.045 11 (44.0%) 6 (16.2%) 0.034
WBC (/µL) 7,707.1 ± 2,325.9 8,161.7 ± 2,558.2 0.314 8,224.3 ± 2,696.4 8,259.6 ± 2,471.9 0.932 8,845.2 ± 3,497.8 8,098.4 ± 2,056.0 0.047 8,973.0 ± 3,130.3 8,967.6 ± 3,056.6 0.995
Eosinophil (/µL) 242.9 ± 169.7 356.8 ± 320.8 0.007 282.9 ± 259.2 436.0 ± 589.0 0.041 81.1 ± 45.9 484.9 ± 467.5 N/A 207.3 ± 181.6 390.6 ± 394.6 0.018
Neutrophil (/µL) 4,452.5 ± 1,793.4 6,111.7 ± 12,225.6 0.202 4,900.7 ± 2,304.8 4,856.4 ± 2,093.8 0.902 7,392.6 ± 12,086.3 4,623.4 ± 2,433.3 0.028 6,059.5 ± 3,117.7 5,346.1 ± 2,555.6 0.347
Serum total IgE (IU/mL) 52.0 ± 30.4 788.4 ± 1,110.9 0 504.8 ± 799.7 521.0 ± 817.6 0.921 340.1 ± 526.1 685.0 ± 1,151.4 0.016 279.6 ± 252.0 449.7 ± 810.1 0.385
Sputum eosinophil (%) 10.1 ± 9.5 12.0 ± 15.5 0.719 13.9 ± 21.0 15.6 ± 17.0 0.791 8.0 ± 19.6 14.6 ± 20.3 0.252 0.3 ± 0.5 20.2 ± 22.5 N/A
Sputum neurophil (%) 36.0 ± 30.5 25.6 ± 25.4 0.314 42.6 ± 34.0 30.9 ± 28.9 0.263 43.5 ± 36.1 41.8 ± 32.9 0.862 49.5 ± 38.8 40.2 ± 31.0 0.302
FeNO (ppb) 26.0 ± 18.4 86.80 ± 60.2 0.24 41.3 ± 7.2 43.0 ± 31.7 0.879 50.0 ± 39.8 50.4 ± 43.7 0.986 38.3 ± 43.1 32.2 ± 11.26 0.728
Pre-BD FEV1 (%) 60.3 ± 16.7 54.5 ± 18.4 0.073 57.6 ± 18.9 54.2 ± 17.0 0.218 58.0 ± 18.8 55.6 ± 17.7 0.27 56.0 ± 16.2 45.7 ± 15.8 0.016
Pre-BD FEV1 (L) 1.7 ± 0.6 1.7 ± 0.7 0.473 1.7 ± 0.6 1.7 ± 0.7 0.846 1.7 ± 0.6 1.7 ± 0.6 0.961 1.6 ± 0.5 1.3 ± 0.6 0.013
Post-BD FEV1/FVC 55.0 ± 8.6 53.9 ± 8.9 0.495 54.8 ± 9.1 54.9 ± 8.9 0.905 55.1 ± 9.5 54.4 ± 9.1 0.557 58.7 ± 8.3 53.1 ± 9.2 0.018
ACT scores (total 25) 21.5 ± 3.6 21.1 ± 3.7 0.711 20.3 ± 4.6 21.3 ± 3.0 0.318 19.7 ± 5.3 20.0 ± 4.2 0.761 16.3 ± 6.1 15.8 ± 5.9 0.835

Data are presented as number (%) or mean ± standard deviation. Bold-styled values denote significant ones.

IgE, immunoglobulin E; ACO, asthma-chronic obstructive pulmonary disease overlap; BMI, body mass index; WBC, white blood cell; N/A, not applicable; FeNO, fractional exhaled nitric oxide; BD, bronchodilator; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ACT, asthma control test.